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IntroductIon
Severe myeloid cytopenia is a serious complication of radia-
tion or chemotherapy and leads to profound susceptibility to 
a variety of opportunistic infections. Myeloablative treatments 
are also required for autologous or allogeneic hematopoietic 
cell transplantation (HCT), a common medical procedure to 
treat hematological disorders. Hematopoiesis from the trans-
planted hematopoietic stem cells (HSCs) and progenitor cells 
(HS/PCs) occurs with a significant lag phase, in which the 
patient shows severe myeloid cytopenia and is vulnerable to 
severe and potentially lethal infections, for example by the 
clinically important gram-negative bacterium Pseudomo-
nas aeruginosa or the fungus Aspergillus fumigatus. Despite 
improved conditioning regimens, better supportive care, and 
new antimicrobial and antifungal agents, infection remains a 
cause of death in 8% of autologous HCT and 17–20% of 
allogeneic HCT recipients (Tomblyn et al., 2009). Antibiotic 
and antifungal prophylaxis during HCT can also be asso-
ciated with significant side effects and does not offer com-
plete protection. These concerns are likely to increase with 
the mounting incidence of multidrug-resistant nosocomial 
strains (To et al., 1997).
Therefore, there is a clear need for alternative treatments 
that could offer protection against infections in the most vul-
nerable early neutropenic phase after HCT. Adoptive transfer 
protocols of myeloid progenitors have been proposed to im-
prove recovery and resulted in protection against lethal infec-
tions of A. fumigatus and P. aeruginosa in a preclinical model 
of HCT (BitMansour et al., 2002, 2005). However, cell ther-
apy approaches require complex logistics and rigorous quality 
control, and their effectiveness and tolerance might be patient 
specific. Cytokines, such as GM-CSF and G-CSF, have also 
been considered as a simple and effective way to shorten my-
eloid cytopenia by enhancing the production and function 
of immune effector cells (Heuser et al., 2007), but meta- 
analyses of clinical studies suggest limited benefit against bacte-
rial or fungal infections (Dekker et al., 2006; Sung et al., 2007; 
Myeloablative treatment preceding hematopoietic stem cell (HSc) and progenitor cell (HS/Pc) transplantation results in severe 
myeloid cytopenia and susceptibility to infections in the lag period before hematopoietic recovery. We have previously shown 
that macrophage colony-stimulating factor (cSF-1; M-cSF) directly instructed myeloid commitment in HScs. In this study, we 
tested whether this effect had therapeutic benefit in improving protection against pathogens after HS/Pc transplantation. 
M-cSF treatment resulted in an increased production of mature myeloid donor cells and an increased survival of recipient mice 
infected with lethal doses of clinically relevant opportunistic pathogens, namely the bacteria Pseudomonas aeruginosa and the 
fungus Aspergillus fumigatus. M-cSF treatment during engraftment or after infection efficiently protected from these patho-
gens as early as 3 days after transplantation and was effective as a single dose. It was more efficient than granulocyte cSF 
(G-cSF), a common treatment of severe neutropenia, which showed no protective effect under the tested conditions. M-cSF 
treatment showed no adverse effect on long-term lineage contribution or stem cell activity and, unlike G-cSF, did not impede 
recovery of HS/Pcs, thrombocyte numbers, or glucose metabolism. these results encourage potential clinical applications of 
M-cSF to prevent severe infections after HS/Pc transplantation.
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De Santa et al., 2009; Tomblyn et al., 2009). In addition, 
G-CSF can result in a loss of long-term repopulating activity 
(de Haan et al., 1995; Bodine et al., 1996; Winkler et al., 2012; 
Schuettpelz et al., 2014).
M-CSF (or CSF-1) is another important myeloid cy-
tokine with multiple roles in myeloid cell biology (Pixley 
and Stanley, 2004). It has found surprisingly little clinical 
applications so far (Metcalf, 2008) but recently gained at-
tention as a potential therapeutic agent (Hume and Mac-
Donald, 2012). We demonstrated before that M-CSF, but 
not GM-CSF or G-CSF, transiently increased myeloid dif-
ferentiation of HSCs by direct activation of the myeloid 
transcription factor PU.1 but did not compromise long-
term stem cell activity (Mossadegh-Keller et al., 2013). 
We therefore reasoned that M-CSF might be effective in 
ameliorating myeloid cytopenias and in protecting patients 
from infection after HCT. To test this hypothesis, we used a 
preclinical mouse model of HS/PC transplantation and in-
fection with lethal doses of the clinically relevant pathogens 
P. aeruginosa or A. fumigatus. We demonstrate that M-CSF 
treatment during transplantation or after infection increased 
myelopoiesis and resulted in substantially improved survival 
and decreased pathogen load, even for early infections and 
single-dose treatments. In contrast, G-CSF showed less ef-
ficient cell recovery and no protective activity against the 
tested pathogens. Our results demonstrate that M-CSF– 
induced myeloid commitment of HSCs rapidly protects 
HCT recipients from lethal infection. They also suggest that 
prophylactic or therapeutic M-CSF treatment during HCT 
could be both more efficient and have less side effects than 
commonly used G-CSF and could complement common 
antifungal or antibacterial drugs.
reSultS And dIScuSSIon
To study whether M-CSF treatment during HCT stimulated 
myelopoiesis and had a beneficial effect against infections, we 
used intraperitoneal injections of P. aeruginosa or intranasal 
instillation with A. fumigatus in a preclinical mouse model 
that mimics potential infection routes in the clinic such as 
common infections via the gastrointestinal tract or i.v. cathe-
ters or inhalation of fungal spores (Latgé, 1999), respectively.
To test the effect of M-CSF on survival after bacterial 
infection, irradiated and HS/PC-transplanted mice received 
either three injections of 10 µg of recombinant M-CSF or 
PBS on the day of HS/PC transplantation (−1 h, 5 h, and 
18 h) and were infected with 500 CFU of P. aeruginosa 7 d 
later (Fig. 1 a), a dose that we had established previously to 
cause 80–90% lethality in untreated transplant-recipient mice. 
Mice that were treated with baculovirus-produced recombi-
nant mouse M-CSF (rmM-CSF) or with bacterially produced 
recombinant human M-CSF (rhM-CSF) showed strongly 
improved survival rates from 15.3% in control to 87.5% in 
rmM-CSF–treated mice (Fig. 1 b) and to 50% in rhM-CSF–
treated mice (Fig.  1  c). All M-CSF–treated mice showed a 
significant decrease of bacterial load in spleen, lung, heart, 
and liver 1 d after infection (Fig. 1 d). This effect correlated 
with increased donor-derived granulocytes and mononuclear 
phagocytes in the spleen and more monocytes and mono-
cyte-derived macrophages in the liver (Fig. 1 e). Similar effects 
were observed in uninfected M-CSF–treated mice (Fig. 1 f). 
M-CSF treatment thus increased myeloid differentiation of 
transplanted HS/PCs and conferred protection against P. 
aeruginosa infection by reducing bacterial tissue load.
To determine whether M-CSF also protected against 
fungal infections, we infected mice 1 wk after irradiation and 
HS/PC transplantation with 4–6 × 106 CFU of A. fumigatus, 
a pathogen dose causing 80–90% lethality in irradiated re-
cipients of life-saving HS/PC transplants. Mice treated with 
rmM-CSF and rhM-CSF during transplantation showed 60% 
(Fig. 2 b) and 40% survival (Fig. 2 c), respectively, compared 
with 10% in the PBS-treated control group. Mice treated with 
rhM-CSF showed a significant decrease in the fungal tissue 
load when compared with control mice in lungs, liver, and 
heart 48 h after infection (Fig. 2 d). These results demonstrated 
that M-CSF treatment also conferred protection against lethal 
A. fumigatus infection by reducing fungal tissue load.
In our assays, both a bacterially expressed bioactive pro-
tein fragment of rhM-CSF as well as baculovirus-expressed 
full-length mouse M-CSF was protective. The somewhat 
lower activity of rhM-CSF might be explained by incom-
plete interspecies cross-reactivity, importance of protein gly-
cosylation or sequences outside of the core fragment, or batch 
or storage variation. Importantly, however, the strong activ-
ity of two different independently produced M-CSF prepa-
rations indicates that the observed effects are a robust and 
general property of M-CSF.
In standard clinical practice, G-CSF is the most com-
mon cytokine used as a prophylactic or treatment option 
in HCT protocols. To directly compare the protective ef-
fect of M-CSF to G-CSF, we treated mice with rmM-CSF, 
rhM-CSF, recombinant human G-CSF (rhG-CSF), or con-
trol PBS during HS/PC transplantation and infection with 
P. aeruginosa. As observed in the previous experiments, 
M-CSF–treated mice showed largely improved survival of 
70% for rmM-CSF or 45.5% for rhM-CSF compared with 
10% in control mice, whereas rhG-CSF–treated mice showed 
no survival improvement (Fig.  3  a). To investigate the un-
derlying reason for the superior protective effect of M-CSF, 
we analyzed the activation of the myeloid PU.1 transcription 
factor as the earliest sign of myeloid lineage commitment 
in HS/PCs (Mossadegh-Keller et al., 2013). We observed a 
strong increase in PU.1+ cells 20 h after M-CSF treatment, 
compared with either PBS controls or G-CSF–treated mice 
in HSCs, but little effect on multipotent progenitors of 
PU.1-GFP reporter mice (Fig. 3, b and c). Consistent with 
our previous observations (Mossadegh-Keller et al., 2013), 
these results suggested that the improved protective effect of 
M-CSF against bacterial infection was because of the early 
and rapid induction of the myeloid commitment of HSCs by 
M-CSF but not by G-CSF.
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Pretransplant treatment with M-CSF can also induce 
the expansion of resident macrophages in HCT recipients 
(Hashimoto et al., 2011). Theoretically, it was therefore pos-
sible that this effect contributed to the protective effect of 
M-CSF against posttransplant infection. To address this, we 
treated irradiated but untransplanted mice with rmM-CSF or 
PBS 1 wk before infection with P. aeruginosa. All M-CSF– 
or PBS-treated mice died within 1–3 d after infection and, 
thus, 2–3 d before control mice died from radiation-induced 
bone marrow failure. In contrast and as observed before, HS/
PC-transplanted and M-CSF–treated mice showed 83.33% 
survival (Fig. 3 c). To increase the time period between in-
fection and irradiation-induced death, we also infected mice 
already 3 d after irradiation and M-CSF treatment (Fig. 3 d). 
Again, all M-CSF– or PBS-treated mice died 1–3 d after 
infection and thus 8–9 d before irradiation-induced death, 
clearly establishing infection as the cause of death. Control 
mice that had received a HS/PC transplant in addition to 
M-CSF showed 37.5% survival even for early infection. In 
the reciprocal experiment, we treated donor mice with PBS 
or M-CSF before HS/PC isolation and infected recipients 
3 d after transplantation of the treated HS/PC graft. Also, in 
Figure 1. M-cSF protects against P. aeruginosa infection by inducing increased myelopoiesis of transplanted HS/Pcs. (a) Lethally irradiated 
CD45.2 mice were transplanted with 2,500 CD45.1 HS/PCs, treated with three doses of control PBS or M-CSF during transplantation (−1 h, 5 h, and 18 h), 
challenged after 1 wk by intraperitoneal injection of 500 CFU of P. aeruginosa, and analyzed for bacterial load and myeloid donor cells 1 d after infection or 
for survival. (b and c) Survival of mice after HS/PC transplantation and bacterial infection (arrow) for PBS control (n = 13) or mice treated with three doses 
of 10 µg of baculovirus-expressed rmM-CSF (n = 8; b) or three doses of 10 µg rhM-CSF (n = 10; c). Transplanted, not infected (black line; n = 4) and irradi-
ated (XR), untransplanted and uninfected control mice (dashed line; n = 6) are shown. P < 0.001 (rmM-CSF) and P < 0.05 (rhM-CSF) by a Mantel-Cox test. 
(d) Bacterial load in indicated organs 18 h after infection of transplanted mice treated with rhM-CSF or control PBS. (e and f) Median of donor monocytes 
(CD11b+, Ly6C+) and monocyte-derived macrophages (CD11b+, Ly6C+, F4/80int) in the liver or granulocytes (Ly6G+, CD11b+) and mononuclear phagocytes 
(Ly6G−, CD11b+) in the spleen of PBS control or M-CSF–treated recipient mice 1 d after infection (e) or 9 d after transplantation of uninfected mice (f). 
Gating strategy is shown in Fig. S1. All data are representative of at least two independent experiments. (d–f) P-values were obtained by Mann-Whitney U 
tests. **, P < 0.01; ***, P < 0.001.
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this protocol, M-CSF but not PBS treatment of donor cells 
resulted in improved survival of transplant recipients infected 
after 3 d, similar to the effect observed for recipient treated 
mice (Fig. 3 e). Together, these experiments clearly establish 
that the protective effect of M-CSF against bacterial infection 
is mediated by its action on donor HS/PCs rather than by 
resident recipient cells.
The effects of M-CSF treatment on early recovery of 
immune competence after HSC transplant might be ex-
plained by its activity on HSC commitment. Whereas other 
myeloid cytokines such as GM-CSF and G-CSF can also 
stimulate proliferation and differentiation of more mature 
myeloid progenitors (Hamilton and Achuthan, 2013) and are 
important at later stages of emergency hematopoiesis (Manz 
and Boettcher, 2014; Zhao and Baltimore, 2015), M-CSF ap-
pears to be unique in its ability to induce myeloid commit-
ment on the HSC level (Sarrazin et al., 2009; Sarrazin and 
Sieweke, 2011; Mossadegh-Keller et al., 2013). This might 
explain why M-CSF treatment provides a critical advantage 
in the early and rapid recovery of myeloid cells and immune 
competence against bacterial and fungal pathogens. Because 
M-CSF is massively induced early after infections (Cheers et 
al., 1988), M-CSF treatment appears to mimic a natural pro-
tective mechanism engaging HSCs in the immune response. 
It will remain to be determined in detail whether the protec-
tive effects depend on increased differentiation to the neu-
trophil or monocyte lineage or both. Some other cytokines 
and growth factors released during infection and inflamma-
tion, including type I and type II interferons, Il-1, IL-6, and 
TNF, can also act on HSCs (Baldridge et al., 2011; King and 
Goodell, 2011; Manz and Boettcher, 2014; Mirantes et al., 
2014; Zhao and Baltimore, 2015) but mainly influence prolif-
erative responses rather than myeloid differentiation of HSCs 
or cause HSC exhaustion. The unique activity of M-CSF on 
HSCs therefore appears to be ideally suited to drive a protec-
tive response against infection during HS/PC transplantation.
Because of these considerations, we further character-
ized the potency of the M-CSF response in various more 
severe infectious conditions. As shown in Fig. 4 a, rmM-CSF–
treated mice infected with P.  aeruginosa already 3 d after 
transplantation also showed significantly improved survival 
of 40% compared with no survival in control or G-CSF–
treated mice. M-CSF–treated mice also showed a significant 
decrease in bacterial load (Fig. 4 b) and increase in donor-de-
rived cells (Fig. 4 c) in the spleen 1 d after early infection. 
Furthermore, mice treated with only a single dose of 10 µg 
rmM-CSF during transplantation also showed improved 
survival of 33.33% in response to infection with P. aerugi-
nosa after 7 d compared with 8.33% survival in control mice 
and no survival in G-CSF–treated mice (Fig.  4  d). Finally, 
transplanted mice infected after 1 wk with P. aeruginosa also 
showed a significant increase of 60% survival compared with 
20% in control mice when rmM-CSF was given after bacte-
rial infection (Fig. 4 e). Collectively, these results demonstrate 
Figure 2. M-cSF protects against A. fumigatus infection after HS/Pc transplantation. (a) Mice were transplanted and treated with M-CSF as de-
scribed in Fig. 1 a, infected after 1 wk by intranasal instillation of A. fumigatus (4–6 × 106 CFU), and analyzed for fungal load after 2 d or for survival. (b and 
c) Survival of mice after HS/PC transplantation and fungal infection (arrow) for PBS control (n = 10) or mice treated with three doses of 10 µg rmM-CSF 
(n = 10; b) or three doses of 10 µg rhM-CSF (n = 10; c). Transplantation (n = 4) and irradiation (XR) controls (n = 4) are shown. P < 0.001 (rmM-CSF) and P 
< 0.01 (rhM-CSF) by Mantel-Cox tests. (d) Fungal load in indicated organs 48 h after infection of transplanted mice treated with rhM-CSF (n = 4) or control 
PBS (n = 4). Photos of cultures from two representative mice are shown. All data are representative of at least two independent experiments.
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Figure 3. Specific M-cSF effect on early HSc commitment correlates with better antibacterial protection than G-cSF during HS/Pc trans-
plantation. (a) Mice were transplanted, treated, and infected as described in Fig. 1 a. Survival of mice after transplantation and bacterial infection (arrow) 
for PBS control (n = 10) or mice treated with rmM-CSF (n = 10), rhM-CSF (n = 11), or rhG-CSF (n = 10) is shown. P < 0.05 (rmM-CSF or rhM-CSF) by a 
Mantel-Cox test. XR, irradiation. (b) Representative FACS profiles and median of GFP expression in HSCs (KSL CD34− Flt3−) and multipotent progenitors 
(MPP; KSL CD34+ Flt3+) of PU.1-GFP reporter mice 20 h after control PBS, rhM-CSF, or rhG-CSF injection. **, P < 0.01 by a Mann-Whitney U test. (c and d) 
Survival of nontransplanted lethally irradiated mice treated with three doses of control PBS (n = 6) or 10 µg rmM-CSF (n = 6) after irradiation (6 h, 12 h, and 
24 h) and challenged after 8 (c) or 3 (d) d (arrow) by i.p. injection of 500 CFU of P. aeruginosa. Control mice were treated identically but transplanted with 
2,500 HS/PCs (n = 6). ****, P < 0.0001 (rmM-CSF + HS/PC) by a Mantel-Cox test. (e) Survival of mice transplanted with donor HS/PCs from mice treated with 
three doses (−5 h, −3 h, and −1 h) of 10 µg rmM-CSF (n = 10) or PBS (n = 8) and infected after 3 d (arrow) with 500 CFU of P. aeruginosa. Control recipient 
mice were treated with three doses of 10 µg rmM-CSF (n = 8) during transplantation. ***, P < 0.001 (rmM-CSF–treated donor HS/PCs) by a Mantel-Cox 
test. Transplantation (n = 4) and irradiation controls (n = 4) are shown in all survival analyses. All data are representative of two independent experiments.
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that both prophylactic and therapeutic M-CSF as single- 
or multiple-dose treatment confer protection to HS/PC- 
transplanted recipients even against early bacterial infection. 
This identifies M-CSF as a potential attractive treatment op-
tion for various clinical needs after HCT.
We furthermore evaluated whether increased my-
eloid lineage commitment after M-CSF treatment affected 
long-term multilineage contribution of transplanted HS/
PCs (Fig. 5 a). We did not detect any difference in the donor 
cell contribution to the myeloid, B cell, or T cell compart-
ments of peripheral blood (Fig. 5 b) or in myeloid-to-lym-
phoid lineage ratio (Fig. 5 c) in M-CSF– or G-CSF–treated 
mice compared with PBS controls. In contrast to G-CSF 
treatment, M-CSF also did not affect donor-derived my-
eloid progenitors or multipotent stem and HS/PC popula-
tions (Fig.  5, d and e). Finally, secondary transplantation of 
bone marrow derived from M-CSF–treated mice, including 
mice that had survived infection, showed robust contribu-
tion to all blood lineages (Fig. 5 f). Thus, our data indicated 
that M-CSF–stimulated myeloid differentiation did not com-
promise general HSC self-renewal, multilineage differentia-
tion capacity, or stem cell activity and did not lead to HSC 
exhaustion or HSC mobilization.
Because earlier clinical studies using long-term treat-
ment with M-CSF for different indications had reported mild 
thrombocytopenia (Garnick and Stoudemire, 1990; Munn et 
Figure 4. M-cSF provides antibacterial protection of HS/Pc transplant recipients for early infection and single-dose or postinfection cyto-
kine treatment. (a) Mice were transplanted and treated with PBS, M-CSF, or G-CSF as described in Fig. 1 a but infected after 3 d. Survival of mice after 
transplantation and bacterial infection (arrow) for PBS control (n = 10) or mice treated with three doses of 10 µg rmM-CSF (n = 10) or rhG-CSF (n = 10) is 
shown. **, P < 0.01 (rmM-CSF) by Mantel-Cox test. XR, irradiation. (b and c) Confocal images with quantification of bacterial colonies (b) or donor cells (c) in 
spleens 24 h after early infection on day 3 of transplanted mice treated with rmM-CSF or control PBS. ****, P < 0.0001 by a Mann-Whitney U test. Bars, 50 
µm. Arrowheads indicate the maximum colony size in the M-CSF–treated group. (d) Mice were transplanted and infected as described in Fig. 1 a but treated 
with a single dose of control PBS, M-CSF, or G-CSF during transplantation (5 h). Survival of mice after transplantation and bacterial infection (arrow) for PBS 
control (n = 12) or mice treated with a single dose of 10 µg rmM-CSF (n = 12) or rhG-CSF (n = 12) is shown. **, P < 0.01 by a Mantel-Cox test. (e) Mice were 
transplanted and infected as described in Fig. 1 a but treated with three doses (1 h, 3 h, and 5 h) of 10 µg rmM-CSF or PBS after infection. Survival of mice 
after transplantation and bacterial infection (arrow) for PBS control (n = 10) or rmM-CSF (n = 12) is shown. *, P < 0.05 by a Mantel-Cox test. Transplantation 
(n = 4) and irradiation controls (n = 4) are shown in all survival analyses. All data are representative of two independent experiments.
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Figure 5. M-cSF treatment does not compromise HSc self-renewal, multilineage differentiation, or stem cell activity. (a) Mice were transplanted 
with actin-GFP HS/PCs and treated with rmM-CSF, rhG-CSF, or PBS as described in Fig. 1 a and analyzed after 17 wk for donor cell contribution in blood 
and bone marrow. (b and c) Percentage of GFP+ donor cell contribution to CD11b+ myeloid, CD19+ B cells, or CD3e+ T cells in blood of reconstituted mice 
(b) or expressed as a ratio of CD11b+ myeloid cells to CD19+ lymphoid cells (c). (d) Percentage of GFP+ donor cell contribution and percentage of total bone 
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al., 1990), we also analyzed platelet recovery after M-CSF 
treatment. Whereas G-CSF treatment led to a significant delay 
of recovery with reduced platelet levels between 1 and 7 wk 
in mice transplanted with actin-GFP HS/PCs, M-CSF treat-
ment showed no disadvantage compared with PBS-treated 
control mice at any time point, and platelet counts recov-
ered to normal homeostatic levels 16 wk after transplantation 
(Fig. 6, b and c). Rare cases of M-CSF–treated patients have 
also been reported with mild hyperglycemia (Bukowski et 
al., 1994), but we did not detect any adverse effects on blood 
glucose levels and body weight of M-CSF–treated mice after 
HS/PC transplantation (Fig. 6 d). The short-term treatments 
during HCT tested here thus did not result in thrombocy-
topenia or hyperglycemia and therefore dissipate concerns 
stemming from earlier clinical studies with long-term con-
tinuous high doses of M-CSF treatment.
Our data indicate that M-CSF treatment during HCT 
appears to have clear advantages over G-CSF both in terms 
of effective protection against bacterial and fungal infec-
tion and reduced side effects on general hematopoietic re-
covery. In contrast to M-CSF treatment, G-CSF treatment 
during HS/PC transplantation led to reduced HSC, progen-
itor, and thrombocyte counts. The ability of G-CSF to in-
duce HSC release into the blood stream that is commonly 
used for HS/PC isolation by leukapheresis might also have 
a negative effect on HSC homing and lodging after HCT. 
Collectively, our findings indicate that M-CSF treatment 
during HCT should likely be more effective and safer than 
the commonly used G-CSF.
Although G-CSF does not increase the production of 
myeloid progenitors from HSCs, it could still have beneficial 
effects on more mature myeloid cells once these progenitors 
have been generated by M-CSF stimulation. Furthermore, a 
recent clinical trial (Wan et al., 2015) reported a benefit of 
GM-CSF over G-CSF for protection from fungal disease in 
transplant recipients. Combinatorial or successive treatment 
marrow cells for c-kit+ progenitors and HS/PCs (KSL). (e) Percentage of GFP+ donor cell contribution to indicated stem and progenitor cell populations. 
(f) Percentage of GFP+ donor cell contribution to myeloid and lymphoid cells in blood 7 wk after secondary transplantation. Error bars represent the median 
with range. *, P < 0.05; **, P < 0.01 by Mann-Whitney U tests. All data are representative of two independent experiments.
Figure 6. M-cSF treatment does not affect platelet recovery or blood glucose levels. (a–c) Mice were transplanted with actin-GFP HS/PCs and 
treated with rmM-CSF, rhG-CSF, or PBS as described in Fig. 1 a and analyzed for donor side scatter (SSC)lo forward scatter (FSC)lo platelet contribution in the 
blood shown as time course of median absolute numbers (b) or quantification at indicated time points (c). Non-irradiated (noXR) nontransplanted controls 
were used as a reference. For 1 wk, * = 0.011 (>0.01 and <0.06). For 7 wk, * = 0.06. (d) Time course of weight and blood glucose levels of mice transplanted 
and treated with rmM-CSF (n = 6) or PBS (n = 6) as indicated in Fig. 1 a. Error bars represent the median and error with interquartile range. **, P < 0.01; ***, 
P < 0.001 by Mann-Whitney U tests. Data are representative of two independent experiments.
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protocols of M-CSF with G-CSF or GM-CSF might there-
fore offer synergistic effects.
Because M-CSF treatment reduces graft-versus-host dis-
ease in allogeneic HCT (Hashimoto et al., 2011; Kimura et al., 
2012), it will be important to determine whether it also has a 
protective effect against infection in this setting, as suggested 
by earlier retrospective clinical observations (Nemunaitis et al., 
1993). In this context, the influence of M-CSF treatment on 
graft-versus-leukemia effects and on residual malignant cells 
will also require further investigation. In summary, the clear 
multiple beneficial effects of M-CSF treatment during HCT on 
improved graft-versus-host disease and protection against clin-
ically important and often lethal fungal and bacterial infections, 
combined with the absence of evident negative side effects 
on reconstitution capacity and hematopoietic differentiation, 
merits consideration of clinical trials of this cytokine in HCT.
MAterIAlS And MetHodS
Mice
CD45.1 and C57BL/6 mice were obtained from Charles 
River. 10–14-wk-old sex-matched CD45.2 recipients 
were reconstituted as previously described (Sarrazin et al., 
2009; Mossadegh-Keller et al., 2013) with bone marrow– 
derived KSL (c-Kit [CD117]+, Sca1+, Lin−) HS/PCs iso-
lated from 6–8-wk-old CD45.1. For in vivo injections, the 
indicated concentrations of M-CSF and/or sorted cells were 
injected in 100–200 µl PBS into the retroorbital sinus. For 
HS/PC transplantation, 2,500 KLS HS/PCs were sorted 
from CD45.1 mice and mixed with 200,000 cKit− CD45.2 
or cKit− Terr119+ carrier CD45.2 cells before injection into 
lethally irradiated (160 kV, 25 mA, and 6.9 Gy) CD45.2 re-
cipient mice. For secondary transplantations, two million 
donor-derived bone marrow cells were injected per lethally 
irradiated recipient. After irradiation, all mice were given an-
tibiotics (Bactrim) in drinking water to reduce the chance 
of opportunistic infection with other pathogens. All mouse 
experiments were performed under specific pathogen–free 
conditions. Animals were handled according to protocols ap-
proved by the animal ethics committee of Marseille, France, 
and were performed in accordance to international, national, 
and institutional regulations.
Isolation of HS/Pcs, cKit−, and cKit− ter119+ cells
Total bone marrow cells were depleted of mature cells by 
staining with biotinylated rat anti–mouse lineage antibody 
cocktail, followed by streptavidin immunomagnetic microbe-
ads (Miltenyi Biotec). Lineage-negative cells were stained 
with HS/PC markers: anti-CD117–APC-H7 (clone 2B8; 
BD), anti–Sca-1–PE-Cy5 (clone D7; BioLegend), strepta-
vidin-APC (eBioscience), and LIVE/DEAD Fixable Vio-
let Dead cell dye (Invitrogen) as viability marker. HS/PCs 
were sorted using FAC SAriaIII equipment (BD). For isolat-
ing cKit− carrier cells, whole bone marrow cells were de-
pleted of cKit+ cells by staining with biotinylated anti–mouse 
CD117 (clone 2B8; BioLegend), followed by streptavidin 
immunomagnetic microbeads (Miltenyi Biotec). For isolat-
ing cKit− Ter119+ carrier cells, first, cKit− cells were selected 
by depleting cKit+ cells, stained with biotinylated anti–mouse 
Ter119 (clone TER-119; BD), and followed by streptavidin 
immunomagnetic beads.
M-cSF treatment
Each mouse received three i.v. injections of 10 µg of each cy-
tokine 1 h before HS/PC transplantation and 5–6 h and 18 h 
after transplantation. rhM-CSF (Novartis), rmM-CSF ex-
pressed in baculovirus, and human G-CSF (Neulasta) were used 
for the study. We thank G. Mouchiroud (Université Claude 
Bernard Lyon I, Villeurbanne, France) for baculovirus- 
produced rmM-CSF.
Infection with P. aeruginosa
The P. aeruginosa PA14 strain was tagged with GFP, as described 
previously (Koch et al., 2001; Giraud et al., 2011). The GFP-
tagged PA14 strain was cultured overnight at 37°C in Luria 
broth medium, diluted 1:100 in Luria broth medium, and grown 
for 3  h to reach bacterial exponential phase (3–4 OD600nm). 
A volume of 100 µl of a bacterial solution of 5 × 103 CFU/ml 
diluted in PBS was further used for infection studies. 1 wk after 
HS/PC transplantation, mice were challenged by intraperitoneal 
inoculation of 500 CFU of bacteria in 100 µl of sterile PBS.
Bacterial tissue load quantification
The infected mice were killed, and the organs (spleen, lungs, 
liver, and heart) were harvested and weighed. To determine 
CFU per gram of tissue, serial dilutions of tissue homoge-
nates were prepared in PBS and plated on Pseudomonas 
Isolation agar (DIF CO), supplemented with appropriate 
antibiotics, and incubated overnight at 37°C. The colonies 
were counted after 16–24 h.
Infection with A. fumigatus
A. fumigatus (FGSC 1100) was provided by the Centre In-
ternational de Ressources Microbiennes– Champignons Fila-
menteux. For each experiment, cultures were grown on malt 
agar medium (2% malt extract and 2% bacto-agar; DIF CO) 
for 5 d at 25°C. Conidial suspension was prepared in sterile 
saline according to a study by BitMansour et al. (2002). 1 wk 
after HS/PC transplantation, mice were infected by intranasal 
inoculation of conidia in 20–40 µl of sterile PBS.
Fungal culture of infected organs
The organs (lungs, liver, heart, and spleen) were harvested and 
weighed, and tissue homogenates were prepared in PBS. The 
homogenates were serially diluted, and 200 µl of each dilution 
was plated on Sabouraud dextrose agar (DIF CO). The plates 
were incubated at 25°C, and pictures were taken after 3–5 d.
Flow cytometry
For FACS sorting and analysis, we used previously described 
staining protocols (Mossadegh-Keller et al., 2013), published 
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stem and progenitor cell definitions (Bryder et al., 2006), 
FAC SCanto, LSR II, and FAC SAriaIII equipment, and DIVA 
software (BD), analyzing only populations with at least 200 
events. The following antibodies were used for staining cells: 
anti-CD117 (clone 2B8; BD), anti–Sca-1 (clone D7; BioLeg-
end), anti-CD34 (clone RAM34; BD), anti-CD16/32 (clone 
2.4G2; BD), anti-CD11b (clone M1/70; BD), anti-CD19 
(clone 1D3; BD), anti-CD3e (clone 145-2C11; BioLegend), 
anti-Ly6G (clone 1A8; BioLegend), anti-Ly6C (clone HK1.4; 
BioLegend), anti-CD115 (clone AFS98; eBioscience), anti- 
CD45.2 (clone 104; BD), anti-CD45.1 (clone A20; BD), 
anti-B220 (clone RA3-6B2; eBioscience), anti-Ter119 (clone 
TER-119; eBioscience), and anti-CD71 (clone R17217; 
eBioscience). LIVE/DEAD Fixable Violet Dead cell dye 
(Invitrogen) was used as a viability marker. Information de-
scribing gating strategies is shown in Figs. S1 and S2.
Immunofluorescence and confocal imaging
Resected spleens were fixed in Antigen-Fix reagent (Diapath) 
for 2 h at 4°C, washed in phosphate buffer, and dehydrated in a 
30% sucrose solution overnight at 4°C. Samples were embed-
ded in TissueTek medium (Sakura), frozen at −80°C, cut into 
8-µm–thick sections using a cryostat, and stained overnight at 
4°C. The following antibodies were used: chicken anti-GFP 
(Aves laboratories) detected with donkey anti–chicken–Alexa 
Fluor 488 (Jackson ImmunoResearch Laboratories, Inc.). 
Confocal microscopy acquisition was performed on a ZEI SS 
microscope (LSM780) at room temperature.
Glycemia test
Blood glucose was monitored every 2 d with a glucometer 
(Performa ACCU-CHEK; Roche).
online supplemental material
Fig. S1 shows gating strategy for donor-derived granulocytes 
and mononuclear phagocytes from spleens and gating strategy 
for donor-derived monocytes and monocyte-derived macro-
phages from livers. Fig. S2 shows gating strategy for quantifi-
cation of actin-GFP+ HS/PC-derived platelets.
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